ReviewClinical cardiology2018
Atrial fibrillation and chronic kidney disease: A review of options for therapeutic anticoagulation to reduce thromboembolism risk.
Review in Clinical cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Systematic Review and Meta-analysis of the Predictive Performance of Stroke and Bleeding Prediction Models in Atrial Fibrillation Patients With Kidney Disease.Kidney medicine · 2026Article
- Association of hemoglobin glycation index with all-cause mortality in critically ill patients with atrial fibrillation: a retrospective analysis from MIMIC-IV.BMC cardiovascular disorders · 2025Observational
- Review
- Effect of Some Risk Factors on Over-Anticoagulation Disorders and Bleeding in Patients Receiving Anticoagulant Therapy with Overdosage of Vitamin K Antagonist.Vascular health and risk management · 2023Article
- Review
- Prevalence of Hemorrhagic Complications in Hospitalized Patients with Pulmonary Embolism.Journal of personalized medicine · 2022Article
- Therapeutic anticoagulation complications in the elderly: a case report.BMC geriatrics · 2022Article
- Article
- Management dilemmas in restarting anticoagulation after gastrointestinal bleeding.Proceedings (Baylor University. Medical Center) · 2022Article
- Impact of estimated glomerular filtration rate on long-term clinical outcomes among Chinese patients with atrial fibrillation.BMC cardiovascular disorders · 2020Article
- Influence of Resveratrol on the Cardiovascular Health Effects of Chronic Kidney Disease.International journal of molecular sciences · 2020Review
- Association of atrial fibrillation and clinical outcomes in adults with chronic kidney disease: A propensity score-matched analysis.PloS one · 2020Article
- Atrial fibrillation and kidney disease: insights on a close relationship.Internal and emergency medicine · 2019Article
- Anticoagulation in chronic kidney disease: from guidelines to clinical practice.Clinical cardiology · 2019Review
- Risks of anticoagulation in patients with chronic kidney disease and atrial fibrillation: More than just bleeding?Research and practice in thrombosis and haemostasis · 2019Article
- Atrial fibrillation and chronic kidney disease: A review of options for therapeutic anticoagulation to reduce thromboembolism risk.Clinical cardiology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation and chronic kidney disease (CKD) commonly occur together, which poses a therapeutic dilemma due to increased risk of both systemic thromboembolism and bleeding. Chronic kidney disease also has implications for medication selection. The objective of this review is to evaluate the options for anticoagulation for thromboembolism prevention in patients with atrial fibrillation and chronic kidney disease. We searched PubMed for studies of patients with atrial fibrillation and CKD on warfarin or a direct oral anticoagulant (DOAC) for thromboembolism prevention through January 1 2018, in addition to evaluating major trials evaluating DOACs and warfarin use as well as society guidelines. For patients with mild to moderate chronic kidney disease, primarily observational data supports the use of warfarin, and high quality trial data and meta-analyses support the use and possible superiority of DOACs. For patients with severe chronic kidney disease, there are limited data on warfarin which supports its use, and data for DOACs is limited primarily to pharmacologic studies which support dose reductions but lack information on patient outcomes. For patients with end-stage renal disease, studies on warfarin are conflicting, but the majority suggest a lack of benefit and possible harm; studies in DOACs are very limited, but apixaban is the least renally cleared and may be both safe and effective. In conclusion, warfarin or DOACs may be used based on the degree of severity of chronic kidney disease, but further study in needed in patients with end-stage renal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.